Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00999544 · ClinicalTrials.gov registry record · NA
Aprepitant Effects on Oxycodone Response
A NA study, sponsored by Sharon Walsh.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT00999544: Completed NA study, sponsored by Sharon Walsh.
NCT00999544 is a NA study that has completed, run by Sharon Walsh. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00999544, a NA study, has completed, sponsored by Sharon Walsh.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects.
Primary Outcome
Visual analog scale ratings (from 0-100) on the subject-rated measure of "How much do you like the drug?" with higher scores indicating greater abuse liability (and 100 anchored with "extremely" and zero indicating none anchored with "none at all." Data were collected across multiple time points but the peak maximum score was used for the primary outcome measure.
Interventions
- DRUG Aprepitant 0mg
- DRUG Aprepitant 40mg
- DRUG Aprepitant 200mg
- DRUG Oxycodone 0mg, p.o.
- DRUG Oxycodone 20mg, p.o.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-04 |
| Phase | NA |
What the finished NCT00999544 record still lists
NCT00999544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which Aprepitant 0mg is the first listed.
NCT00999544 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00999544 about?
NCT00999544 is a clinical study titled "Aprepitant Effects on Oxycodone Response". Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute...
What is the current status of trial NCT00999544?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2009-10. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00999544?
The interventions under investigation include: Aprepitant 0mg (DRUG), Aprepitant 40mg (DRUG), Aprepitant 200mg (DRUG), Oxycodone 0mg, p.o. (DRUG), Oxycodone 20mg, p.o. (DRUG).
Who is sponsoring clinical trial NCT00999544?
This trial is sponsored by Sharon Walsh, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00999544's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia